Pfizer Weighs Options For Future Of Established Products Business Unit As Revenues Show Strong Trends: Emerging Markets Earnings Roundup (Part 3)
This article was originally published in PharmAsia News
Executive Summary
Emerging markets remained a key focus of Big Pharma during first quarter earnings calls, with many highlighting exceptional growth in these markets, particularly China. Perhaps the most interesting Q call of all was Pfizer Inc., which discussed in more detail whether it plans to spin out its emerging markets unit.
You may also be interested in...
Sale Of Pfizer’s Established Products Not Off The Table, Exec Says
Pfizer CFO Frank D’Amelio talks about the big pharma’s long-term vision and cost-reduction initiatives during the Morgan Stanley Healthcare conference. Management will continue reviewing the portfolio on an ongoing basis to see how best to maximize shareholder value, he said.
Sale Of Pfizer’s Established Products Not Off The Table, Exec Says
Pfizer CFO Frank D’Amelio talks about the big pharma’s long-term vision and cost-reduction initiatives during the Morgan Stanley Healthcare conference. Management will continue reviewing the portfolio on an ongoing basis to see how best to maximize shareholder value, he said.
Hot Opportunities In The African Emerging Markets - A Look At South Africa (Part 1 of 2)
Although the fast-growing South African pharmaceutical market is dominated by local generic firms, multinational pharma companies are also seeing significant growth through new initiatives and product launches, said investment firm Credit Suisse in a September report based on IMS Health data